1. Multimodal electrophysiological analyses reveal that reduced synaptic excitatory neurotransmission underlies seizures in a model of NMDAR antibody-mediated encephalitis.
- Author
-
Wright, Sukhvir K., Rosch, Richard E., Wilson, Max A., Upadhya, Manoj A., Dhangar, Divya R., Clarke-Bland, Charlie, Wahid, Tamara T., Barman, Sumanta, Goebels, Norbert, Kreye, Jakob, Prüss, Harald, Jacobson, Leslie, Bassett, Danielle S., Vincent, Angela, Greenhill, Stuart D., and Woodhall, Gavin L.
- Subjects
- *
TREATMENT of epilepsy , *ELECTROPHYSIOLOGY , *NEURAL transmission , *METHYL aspartate receptors , *AUTOANTIBODIES - Abstract
Seizures are a prominent feature in N-Methyl-D-Aspartate receptor antibody (NMDAR antibody) encephalitis, a distinct neuro-immunological disorder in which specific human autoantibodies bind and crosslink the surface of NMDAR proteins thereby causing internalization and a state of NMDAR hypofunction. To further understand ictogenesis in this disorder, and to test a potential treatment compound, we developed an NMDAR antibody mediated rat seizure model that displays spontaneous epileptiform activity in vivo and in vitro. Using a combination of electrophysiological and dynamic causal modelling techniques we show that, contrary to expectation, reduction of synaptic excitatory, but not inhibitory, neurotransmission underlies the ictal events through alterations in the dynamical behaviour of microcircuits in brain tissue. Moreover, in vitro application of a neurosteroid, pregnenolone sulphate, that upregulates NMDARs, reduced established ictal activity. This proof-of-concept study highlights the complexity of circuit disturbances that may lead to seizures and the potential use of receptor-specific treatments in antibody-mediated seizures and epilepsy. Sukhvir Wright et al. present a NMDAR antibody-induced model of encephalitis in rats and use in vitro, in vivo, and in silico electrophysiology to examine alterations in neural circuit behavior. Their results suggest that reduction of NMDARs leads to increased excitability and seizure activity, and highlights the potential use of receptor-specific treatments in antibody-mediated seizures and epilepsy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF